Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250.

• DOI: 10.1200/jco.1993.11.4.738
• Publication Date: 2017-02-23T13:42:24Z
• Authors: E Oosterwijk; N H Bander; C R Divgi; S Welt; J C Wakka; R D Finn; E A Carswell; S M Larson; S O Warnaar; G J Fleuren
• Keywords: Biodistribution

PURPOSE To define the imaging and biodistribution characteristics of iodine 131-labeled monoclonal antibody (mAb) G250 (131I-mAbG250), which recognizes a cell-surface antigen expressed by human renal cell carcinoma (RCC). PATIENTS AND METHODS is recognized mAbG250 RCC but not detected in normal kidney. Clear-cell RCC, most frequent form shows homogeneous expression G250, whereas non-clear-cell cancers derived from other organs generally do express G250. Expression tissues highly restricted limited to large bile ducts gastric epithelium. 131I-mAbG250 was administered intravenously (IV) 16 patients with 7 8 days before surgery at five dose levels, least three entered each level. RESULTS Clear tumor images were observed 12 G250-positive tumors one G250-negative tumors. Imaged lesions peritoneal cavity confirmed surgery. The smallest lesion visualized mm diameter. specificity localization tissue established radioactivity measurements, autoradiography, immunohistochemistry biopsied tissues, technetium 99-human serum albumin blood-flow studies. fraction injected per gram (%ID/g tumor) localized showed broad range, reached levels as high 0.02% 0.12%. CONCLUSION specifically antigen-positive seems have considerable potential an agent patients. uptake tumors, relative well absolute, are among highest reported for biopsies obtained after IV mAb administration. Based on specific accumulation, may therapeutic potential.